Cargando…

Prevalence of familial autoimmune diseases in juvenile idiopathic arthritis: results from the international Pharmachild registry

BACKGROUND: Little is known about the disposition to autoimmune diseases (ADs) among children diagnosed with JIA. In this study, we provide a comprehensive overview of the prevalence of and factors associated with ADs in parents of children with juvenile idiopathic arthritis (JIA). METHODS: Prevalen...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Straalen, Joeri W., de Roock, Sytze, Giancane, Gabriella, Alexeeva, Ekaterina, Koskova, Elena, Mesa-del-Castillo Bermejo, Pablo, Zulian, Francesco, Civino, Adele, Montin, Davide, Wulffraat, Nico M., Ruperto, Nicolino, Swart, Joost F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673358/ https://www.ncbi.nlm.nih.gov/pubmed/36401230 http://dx.doi.org/10.1186/s12969-022-00762-y

Ejemplares similares

Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry
por: van Straalen, Joeri W., et al.
Publicado: (2023)

Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries
por: Swart, Joost, et al.
Publicado: (2014)

Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
por: Giancane, Gabriella, et al.
Publicado: (2020)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
por: Swart, Joost, et al.
Publicado: (2018)

What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
por: Swart, Joost F, et al.
Publicado: (2013)

Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2021)

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2023)

A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis
por: van Straalen, Joeri W, et al.
Publicado: (2020)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Development and External Validation of a Model Predicting New‐Onset Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients
por: Swart, Joost F, et al.
Publicado: (2019)

Monitoring patients with juvenile idiopathic arthritis using health-related quality of life
por: Doeleman, Martijn J. H., et al.
Publicado: (2021)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Wulffraat, Nico, et al.
Publicado: (2018)

The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Nikishina, Irina, et al.
Publicado: (2018)

Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis
por: Kip, Michelle M A, et al.
Publicado: (2022)

Costs of Hospital‐Associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System
por: Kip, Michelle M. A., et al.
Publicado: (2022)

PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis
por: Wienke, J, et al.
Publicado: (2013)

Drivers of non-zero physician global scores during periods of inactive disease in juvenile idiopathic arthritis
por: Alongi, Alessandra, et al.
Publicado: (2022)

The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Dehoorne, Joke, et al.
Publicado: (2018)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals?
por: Schoemaker, Casper G., et al.
Publicado: (2020)

Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study
por: Quartier, Pierre, et al.
Publicado: (2020)

Current evidence for the medical treatments of systemic juvenile idiopathic arthritis
por: Ruperto, Nicolino
Publicado: (2014)

Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients
por: Consolaro, Alessandro, et al.
Publicado: (2014)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

A three minute- screening tool for temporomandibular joint involvement in children with juvenile idiopathic arthritis
por: Giancane, Gabriella, et al.
Publicado: (2014)

Current Medical Treatments for Juvenile Idiopathic Arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2011)

Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey
por: Papa, Riccardo, et al.
Publicado: (2020)

Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era
por: Giancane, Gabriella, et al.
Publicado: (2019)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients
por: Giancane, Gabriella, et al.
Publicado: (2019)

The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Norambuena, Ximena, et al.
Publicado: (2018)

The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Pruunsild, Chris, et al.
Publicado: (2018)

The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Ioseliani, Maka, et al.
Publicado: (2018)

The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Boyko, Yaryna, et al.
Publicado: (2018)

The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Ekelund, Maria, et al.
Publicado: (2018)

The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis
por: Hamad Saied, Mohamad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r8b8sehtjlocfauectdsu4qb0l